GlassScriptPhysician profile
Jodi Watson Rose
NPI 1124494513
$56,987.09
in general payments reported to CMS, 2019-2025
66 companies · $4,808 in 2025
The $4,808 reported for 2025 was more than what 99% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $22K · 2022: $22K · 2023: $4,669 · 2024: $4,318 · 2025: $4,808.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Travel and Lodging: $805 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,877.97 |
| Travel and Lodging | $805.13 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $20,193.99 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18,136.76 | 2021 | |
| Abbvie INC. | $2,170.19 | 2021-2025 | |
| Ucb, INC. | $1,809.93 | 2021-2025 | Briviact, Fintepla, Nayzilam |
| Livanova USA, INC. | $1,291.44 | 2025 | Vns Therapy |
| Acadia Pharmaceuticals INC | $915.69 | 2021-2025 | Nuplazid |
| Emd Serono, INC. | $862.79 | 2021-2025 | Mavenclad |
| Lundbeck LLC | $793.91 | 2021-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $732.94 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Neurocrine Biosciences, INC. | $676.25 | 2021-2025 | Ingrezza, Ongentys |
| Neurelis, INC. | $676.11 | 2021-2025 | Valtoco |
| Pfizer INC. | $645.58 | 2021-2025 | |
| Argenx US, INC. | $607.21 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $604.93 | 2021-2025 | Vumerity, Tysabri, Skyclarys |
| Eisai INC. | $591.68 | 2021-2025 |
Show all 66 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $579.38 | 2021-2025 | |
| Alexion Pharmaceuticals, INC. | $554.46 | 2021-2025 | Ultomiris |
| Celgene Corporation | $456.99 | 2021-2025 | Zeposia |
| Lilly USA, LLC | $441.91 | 2021-2025 | Amyvid, Emgality, Kisunla |
| Sk Life Science, INC. | $373.91 | 2021-2025 | Xcopri |
| Sumitomo Pharma America, INC. | $246.67 | 2023-2024 | Aptiom |
| Mdd US Operations, LLC | $217.91 | 2021-2023 | Gocovri |
| Sunovion Pharmaceuticals INC. | $213.48 | 2021-2022 | |
| Csl Behring | $207.23 | 2021-2024 | Hizentra |
| Kyowa Kirin, INC. | $181.92 | 2022-2024 | Nourianz |
| Catalyst Pharmaceuticals, INC. | $180.91 | 2023-2025 | Fycompa |
| Otsuka America Pharmaceutical, INC. | $175.92 | 2023-2025 | Nuedexta, Rexulti |
| Upsher-Smith Laboratories LLC | $141.82 | 2021 | |
| Jazz Pharmaceuticals INC. | $141.51 | 2023-2025 | |
| Nevro Corp. | $141.40 | 2023 | Senza |
| Amneal Pharmaceuticals LLC | $125.84 | 2021-2025 | Crexont, Rytary |
| Corium, LLC | $123.57 | 2022-2023 | Adlarity |
| Janssen Pharmaceuticals, INC | $101.32 | 2021-2022 | |
| Genzyme Corporation | $94.12 | 2022-2025 | |
| Avanir Pharmaceuticals, INC. | $93.95 | 2021-2022 | |
| Banner Life Sciences, LLC | $88.67 | 2022-2024 | |
| Octapharma USA, INC. | $84.58 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Scilex Pharmaceuticals INC. | $80.10 | 2023-2025 | Ztlido |
| Acorda Therapeutics, INC | $72.85 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $71.70 | 2021-2025 | Wainua, Andexxa |
| Genentech USA, INC. | $70.54 | 2021-2024 | Ocrevus, Ocrevus Zunovo |
| Impel Pharmaceuticals INC. | $65.41 | 2023 | Trudhesa |
| Janssen Biotech, INC. | $62.10 | 2025 | |
| Allergan, INC. | $61.52 | 2021 | |
| Arbor Pharmaceuticals, INC. | $60.88 | 2021 | |
| Ani Pharmaceuticals, INC. | $58.16 | 2023 | Purified Cortrophin Gel |
| Cycle Pharmaceuticals INC | $58.07 | 2024-2025 | Tascenso Odt, Bafiertam |
| Tanabe Pharma America, INC. | $56.62 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $54.56 | 2024-2025 | Acthar |
| Supernus Pharmaceuticals, INC. | $53.50 | 2021-2023 | |
| Amylyx Pharmaceuticals, INC. | $51.63 | 2023-2024 | Relyvrio |
| Tg Therapeutics, INC. | $43.97 | 2023-2024 | |
| E.R. Squibb & Sons, L.L.C. | $42.95 | 2021 | |
| Medtronic, INC. | $41.01 | 2021-2022 | |
| Boston Scientific Corporation | $37.60 | 2025 | Wavewriter Alpha Prime 16 |
| Amgen INC. | $35.89 | 2023-2025 | Aimovig, Uplizna |
| Axsome Therapeutics, INC. | $35.39 | 2025 | Symbravo |
| Adamas Pharmaceuticals, INC. | $31.66 | 2021 | |
| Vanda Pharmaceuticals INC. | $29.65 | 2025 | Ponvory |
| Grifols USA, LLC | $26.17 | 2025 | Gamunex-C |
| Takeda Pharmaceuticals U.S.A., INC. | $24.68 | 2023 | |
| Averitas Pharma INC. | $23.08 | 2024 | Qutenza |
| Almatica Pharma LLC | $19.07 | 2021 | |
| Sandoz INC. | $15.16 | 2023 | |
| Merz Pharmaceuticals, LLC | $13.92 | 2025 | Xeomin |
| Alnylam Pharmaceuticals INC. | $12.38 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jodi Rose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.